![]() The integrated product platform would be developed by Debiotech and will be commercialized by partners selected by Debiotech. ![]() The partnership contemplated through this option is intended to deliver a complete solution to diabetic patients, combining the unique features of Debiotech's JewelPUMPTM and "All-in-One" remote control data communication device with the highly accurate, particularly easy to use and comfortable CGM sensor of iSense CGM, Inc. The JewelPUMPTM is also equipped with an intuitive and highly secured Telemedicine enabled "All-in-One" Remote Control device. The JewelPUMPTM is today's most integrated patch pump product, combining the highest insulin delivery accuracy with the largest insulin reservoir (5mL) for both Type 1 and Type 2 patients. With close to 390 million people in the world having diabetes today (a number predicted to grow to around 592 million by 2035) and numerous studies showing the interest of combining accurate insulin delivery and Continuous Glucose Monitoring, it is of upmost importance to offer a reliable integrated approach for a more effective treatment of diabetes. Financial terms and conditions of the Agreement are not disclosed. ![]() of the US, announced today having entered into an Agreement under which Debiotech has the option to acquire the exclusive rights on the iSense CGM product and technology for use with patch pumps for diabetes therapy. Debiotech agrees to acquire exclusive rights on iSense CGM technology for use with patch pumpsÄebiotech of Switzerland and iSense CGM, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |